Start enrolling patients for the RP3 and Opdivo combination trial
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 3 Feb 2022
- Due
- 31 Mar 2022
- Delivered
- March 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The Company expects to start enrolling patients to be treated with RP3 in combination with Opdivo this quarter”
What we found
Evidence strength A What the grades mean
The company confirmed in a May 2022 filing that enrollment for the RP3 and nivolumab (Opdivo) combination cohort had begun in March 2022, meeting the Q1 2022 deadline.
-
A Replimune Group, Inc. 8-K filed 2022-05-19
“Following determination of the recommended Phase 2 dose (RP2D), enrollment into the cohort of patients dosed with RP3 combined with Opdivo has recently commenced.” ✓ confirmed on the page
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Start
- Deliverable
- RP3 and Opdivo combination trial enrollment
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Customer
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Replimune Group, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-REPL-002664 · Corrections policy